Wednesday, May 27, 2009

Link: CU Awarded Patent for Cancer Rx; Viral Genetics Holds Option

Via Biotech Transfer Week: Biotech company Viral Genetics said last week that the University of Colorado has recently been issued what it believes to be the first US patent related to a new treatment for drug-resistant cancer known as metabolic disruption. (See US 7,510,710, "Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor, and/or a glucose metabolism inhibitor."

Viral Genetics, based in San Marino, Calif., holds an exclusive option to acquire the rights to the intellectual property, which adds to a portfolio of IP the company had previously licensed from CU based on the work of M. Karen Newell Rogers, a professor of biology at the University of Colorado, Colorado Springs.

Read the full article.

Thursday, May 21, 2009

Link: Boulder Innovation Center Metrics Report Points to Entrepreneurial Renaissance

CU TTO partner Boulder Innovation Center (BIC) today released its Metrics Report for 2008, indicating strong economic growth within Boulder’s entrepreneurial ecosystem. In 2008, the BIC was instrumental in forming four new start-up companies commercializing technology from the University of Colorado: 3QMatrix, Line Rate Systems, ION Engineering and Tusaar.

Wednesday, May 20, 2009

CU Announces Second Round of Renewable Energy Commercialization Grants

Proof-of-concept grants will help CU energy and cleantech technology to become commercially viable (LINK)

BOULDER (May 20, 2009). The University of Colorado has selected three projects for funding in the second round of a grant program designed to bring the projects closer to becoming commercial products. Earlier in 2009, the CU Technology Transfer Office (TTO) and the CU-Boulder Energy Initiative (EI) formed a partnership to award these grants, known as ‘proof of concept’ grants, to support commercialization of promising energy and cleantech technologies. The projects were selected for funding by the TTO and EI using a competitive internal application process. The winning grant proposals were:
David Denkenberger and John Zhai, for a demonstration of an improved micro-channel heat management device for power plants, energy-efficient vehicles and buildings, and other industrial applications.

Conrad Stoldt and Se-Hee Lee, for work on improved performance of lithium-ion (Li+) batteries via solid-state nanostructuring.

Robert Erickson, for a project on ‘smart’ power electronics for photovoltaic panels that maximize the energy captured by each panel. This proposal was funded as a $50,000 proof of concept investment to Phobos Energy, a University of Colorado startup company based on technology from Dr. Erickson’s CU-Boulder lab.
To learn more about POC grants for renewable energy research, please visit the TTO website.

May 2009 Newsletter Now Available

Highlights from TTO's May 2009 newsletter:

GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
In May, CU licensee GlobeImmune, Inc. and Celgene Corporation announced a worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on powerful, targeted molecular immunotherapy for the treatment of cancer. Under the terms of the agreement, GlobeImmune will receive a $40 million upfront payment from Celgene, which includes an equity investment in GlobeImmune.

InDevR Licenses CU FluChip Technology to Combat Deadly Swine Flu Virus
InDevR Inc., a small biotech company in Boulder, announced in late April that they have licensed the FluChip technology from the University of Colorado. The FluChip was invented by a joint team of scientists at the University of Colorado and the Centers for Disease Control and Prevention, in an NIH-sponsored effort led by Professor Kathy Rowlen. Rowlen, now the CEO of InDevR, said that InDevR has arranged to test genetic material from the recent swine H1N1 virus on the MChip as well as other versions of the FluChip which are under development.

BlueSun, Inc. Commercializing CU Trauma Recovery Program
Colorado Springs-based BlueSun, Inc. has finalized an agreement with the University of Colorado to license the Journey to Disaster Recovery™ and Journey to Trauma Recovery™ programs developed by Dr. Charles Benight and his collaborators at the Trauma, Health, and Hazards Center and the Computer Science Department at the University of Colorado at Colorado Springs. The Journey to Recovery™ websites are ideal for disaster recovery situations where traumatized individuals have little access to recovery assistance due to environmental logistics – for example, when there are few mental health providers available – and in situations where public movement is restricted like a pandemic influenza outbreak, or when people fear being labeled because they are accessing mental health services.

CU Graduate Programs Remain Among the Nation’s Best
Twenty-eight academic programs across the university’s campuses in Boulder, Colorado Springs and Denver, including the Anschutz Medical Campus in Aurora, remain nationally ranked in the 2010 U.S. News & World Report graduate school rankings released in late April. The magazine ranked three graduate programs at the UC Denver School of Medicine among the top 10 in the nation, including family medicine at third, primary care at fourth, and pediatrics at eighth. CU-Boulder’s atomic, molecular and optical physics program is top-ranked nationally, quantum physics program is fourth, and plasma physics is ranked 10th nationally. CU-Boulder’s Deming Center for Entrepreneurship at the Leeds School of Business was also ranked in the top 20 business school programs.

Read the full newsletter.

Tuesday, May 19, 2009

Tech Spotlight: Novel therapeutics for prostate cancer bone metastases

A University of Colorado research team led by Dr. Lajos Gera has developed a compound that directly inhibits survivin and effectively retards skeletal growth of human prostate cancer. The compound is BKM1740, a bradykinin antagonist previously shown to suppress tumor growth, conjugated with bis-phosphonate, which targets the compound to bone. Dr. Gera has in vitro data showing that 2-10μM of BKM1740 is able to induce 20-80% apoptosis, respectively, in metastatic prostate cancer cells.

To read a non-confidential summary of this technology, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.

Wednesday, May 13, 2009

Link: Colorado in Top 5 Regions Targeting Biotech

FierceBiotech released a report today compiling the top 5 regions in the U.S. targeting biotech, and Colorado made the cut:
$26.5 million [provided by HB 08-1001] can't compare to the kind of money that California, Massachusetts, Florida and others have already spent fostering biotech. But it is a cleverly designed program that has real potential to help emerging biotech companies -- as well as state researchers and institutions -- when they need it the most. Combined with a few more scientific recruiting coups, Colorado could start to realize its latent potential.
Read the full report.

Monday, May 11, 2009

Podcast: Dr. Hubert Yin, CU-Boulder New Inventor of the Year

W3W3 radio talked with CU-Boulder's Hubert Yin about his work identifying potential treatments for pain which avoiding the side effects of morphine and other opioid drugs. Dave Allen, CU Associate Vice President for Technology Transfer, sat in on this inspiring interview.

Listen to the podcast.

Friday, May 8, 2009

Job Opportunity: Chemistry/Chemical Engineering Licensing Associate

The CU Technology Transfer Office is seeking a Chemistry or Chemical Engineering Licensing Associate for its Boulder office. The Licensing Associate identifies, solicits, and evaluates invention disclosures for patent and market potential; markets technologies to commercial partners; and tracks and develops a portfolio of associated intellectual property. Please review the full requirements - to apply, visit www.jobsatcu.com (posting #807021).

Tuesday, May 5, 2009

Tech Spotlight: Sustained-release drug delivery composition including amorphous polymer

A group of University of Colorado researchers led by Dr. Theodore Randolph have devised a technique to place a pharmaceutical substance into solution in an organic solvent in the form of a hydrophobic ion pair complex with an amphiphilic material. The resulting solution may then be subjected to gas antisolvent precipitation using a near critical or supercritical fluid to produce a precipitate of particles comprising the pharmaceutical substance. Particles may be produced with a relatively narrow size distribution in a variety of sizes, permitting flexibility in preparing particles for effective utilization in a variety of pharmaceutical applications.

To read a non-confidential summary of this technology, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.